| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00401-008-0344-8 |
| P698 | PubMed publication ID | 18231798 |
| P50 | author | Glenda Halliday | Q45304807 |
| John C. Morris | Q56839763 | ||
| P2093 | author name string | Mariese Hely | |
| Wayne Reid | |||
| P2860 | cites work | Cognitive status correlates with neuropathologic stage in Parkinson disease | Q48914894 |
| P433 | issue | 4 | |
| P921 | main subject | pathology | Q7208 |
| Parkinson's disease | Q11085 | ||
| patient | Q181600 | ||
| P304 | page(s) | 409-415 | |
| P577 | publication date | 2008-01-30 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | The progression of pathology in longitudinally followed patients with Parkinson's disease. | |
| P478 | volume | 115 |
| Q37598503 | A clinico-pathological study of subtypes in Parkinson's disease |
| Q30545574 | A three dimensional anatomical view of oscillatory resting-state activity and functional connectivity in Parkinson's disease related dementia: An MEG study using atlas-based beamforming |
| Q89555380 | APOE genotype regulates pathology and disease progression in synucleinopathy |
| Q64862623 | APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology |
| Q47617157 | Advanced Parkinson disease patients have impairment in prosody processing. |
| Q37668932 | Ageing, neurodegeneration and Parkinson's disease |
| Q27003541 | Alpha-synuclein biology in Lewy body diseases |
| Q47138744 | Altered emotional recognition and expression in patients with Parkinson's disease |
| Q35603195 | Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review |
| Q58096576 | Amyloid-β and Parkinson's disease |
| Q38161789 | Amyotrophic lateral sclerosis--a model of corticofugal axonal spread |
| Q36758618 | An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology |
| Q39012982 | An order in Lewy body disorders: Retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal/multifocal Lewy body disease |
| Q34327937 | An update on brain imaging in parkinsonian dementia |
| Q54982491 | Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? |
| Q42178133 | Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population. |
| Q45816941 | Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease. |
| Q42501188 | Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology |
| Q33634944 | BAG2 structure, function and involvement in disease |
| Q36373170 | Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. |
| Q42917168 | Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model |
| Q53512229 | CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. |
| Q26744782 | Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease |
| Q34237637 | Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions |
| Q99566271 | Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson's disease |
| Q37631957 | Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. |
| Q38761399 | Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression |
| Q35923461 | Clinico-pathological correlations of the most common neurodegenerative dementias. |
| Q61803900 | Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders |
| Q36486037 | Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice |
| Q47990737 | Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles |
| Q33619119 | Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease |
| Q40364232 | Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases |
| Q57997350 | Cortical Thinning and Cognitive Impairment in Parkinson's Disease without Dementia |
| Q37030350 | Cortical thinning is associated with disease stages and dementia in Parkinson's disease |
| Q37578245 | Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders |
| Q37970685 | Dementia after DBS Surgery: A Case Report and Literature Review |
| Q45366108 | Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease |
| Q48274381 | Different Functional and Microstructural Changes Depending on Duration of Mild Cognitive Impairment in Parkinson Disease. |
| Q34336792 | Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease |
| Q28293967 | Distinct α-synuclein strains differentially promote tau inclusions in neurons |
| Q48575031 | Distribution and Load of Amyloid-β Pathology in Parkinson Disease and Dementia with Lewy Bodies |
| Q48446897 | Dopaminergic basis for impairments in functional connectivity across subdivisions of the striatum in Parkinson's disease |
| Q38051969 | Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia |
| Q45289583 | EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. |
| Q33835242 | Embryonic development of selectively vulnerable neurons in Parkinson's disease. |
| Q47320399 | Epigenetics in Parkinson's Disease |
| Q64785198 | Episodic recognition memory and the hippocampus in Parkinson's disease: A review |
| Q34591096 | Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease |
| Q38014888 | Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? |
| Q34552244 | Exploring Braak's Hypothesis of Parkinson's Disease. |
| Q52688719 | Facial emotion recognition in Parkinson's disease: A review and new hypotheses. |
| Q37587790 | Formation and development of Lewy pathology: a critical update |
| Q64765351 | Frontal atrophy as a marker for dementia conversion in Parkinson's disease with mild cognitive impairment |
| Q34463167 | Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. |
| Q36175217 | Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process |
| Q42177449 | Habitual behavior and dopamine cell vulnerability in Parkinson disease |
| Q64087023 | Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinson's disease with cognitive decline |
| Q48312842 | How well do we recognise non-motor symptoms in a British Parkinson's disease population? |
| Q38003065 | Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease |
| Q38368611 | Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes |
| Q30678856 | Imaging: What can it tell us about parkinsonian gait? |
| Q45844417 | Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease |
| Q62740597 | Impulsivity across reactive, proactive and cognitive domains in Parkinson's disease on dopaminergic medication: Evidence for multiple domain impairment |
| Q36004679 | Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? |
| Q39094808 | Integrating Patient Concerns into Parkinson's Disease Management |
| Q40413085 | Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease. |
| Q30277323 | Investigation of Genetic Variants Associated with Alzheimer Disease in Parkinson Disease Cognition |
| Q89251186 | Is Braak staging valid for all types of Parkinson's disease? |
| Q39206438 | LRRK2 and the Immune System |
| Q38003064 | Lewy pathology and neurodegeneration in premotor Parkinson's disease |
| Q34327102 | Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? |
| Q36424977 | Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α-synuclein mutation |
| Q38085592 | Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease? |
| Q48384941 | Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease |
| Q37864573 | Mild cognitive impairment in Parkinson's disease. |
| Q37882587 | Milestones in Parkinson's disease--clinical and pathologic features |
| Q22251063 | Missing pieces in the Parkinson's disease puzzle |
| Q38286574 | Models of α-synuclein aggregation in Parkinson's disease |
| Q57498331 | Molecular Imaging of the Cholinergic System in Parkinson's Disease |
| Q50732522 | Motor profile and drug treatment of nursing home residents with Parkinson's disease. |
| Q37185684 | Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes |
| Q34635272 | National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease |
| Q30527797 | Neuropathologic substrates of Parkinson disease dementia |
| Q37693339 | Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff |
| Q30833019 | Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis |
| Q37631959 | Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria |
| Q38794098 | Neuropathological basis of nonmotor manifestations of Parkinson's disease |
| Q42108095 | Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease |
| Q64759312 | Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders |
| Q57306342 | Neuropathology of Dementia in Parkinson's Disease |
| Q37677151 | Neuropathology of non-motor features of Parkinson disease |
| Q37955871 | Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts |
| Q38580816 | Neuropathology of α-synuclein propagation and braak hypothesis |
| Q37896515 | Neuropathology underlying clinical variability in patients with synucleinopathies |
| Q37950422 | Nonmotor symptoms in Parkinson's disease |
| Q35884908 | Nonmotor symptoms of Parkinson's disease |
| Q51855914 | PDD-Short Screen: a brief cognitive test for screening dementia in Parkinson's disease. |
| Q42696784 | Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease |
| Q30248574 | Parkinson Disease and Dementia |
| Q22242000 | Parkinson's Disease: Genetics and Pathogenesis |
| Q54072241 | Parkinson's disease |
| Q29616302 | Parkinson's disease |
| Q37739308 | Parkinson's disease dementia. |
| Q27686837 | Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies |
| Q33797449 | Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis |
| Q53301649 | Pathologic confirmation of retinal ganglion cell loss in multiple system atrophy. |
| Q39071493 | Pathology of Neurodegenerative Diseases |
| Q42054485 | Pattern of Reduced Functional Connectivity and Structural Abnormalities in Parkinson's Disease: An Exploratory Study |
| Q34566376 | Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease |
| Q37968067 | Patterns of α-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease |
| Q37677153 | Predicting Parkinson's disease - why, when, and how? |
| Q35910731 | Premotor Parkinson's disease: concepts and definitions |
| Q64785442 | Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease |
| Q27322513 | Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies |
| Q48371760 | Purine metabolism gene deregulation in Parkinson's disease |
| Q48259289 | Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study |
| Q48247020 | Relationships between age and late progression of Parkinson's disease: a clinico-pathological study |
| Q39095738 | Selective neuronal vulnerability in Parkinson disease |
| Q89059778 | Sensitivity and specificity of phospho-Ser129 α-synuclein monoclonal antibodies |
| Q48685847 | Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. |
| Q33860315 | Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease |
| Q37681251 | Sleep disturbances in Parkinson disease and their potential role in heterogeneity |
| Q48361804 | Small-vessel disease in patients with Parkinson's disease: a clinicopathological study. |
| Q38652662 | Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology |
| Q43954098 | Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease |
| Q36494215 | Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease |
| Q44212444 | Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease |
| Q38704236 | Synaptic failure and α-synuclein |
| Q36106447 | Synthesis and in vitro evaluation of α-synuclein ligands. |
| Q39003423 | Synucleinopathies: common features and hippocampal manifestations |
| Q64814715 | The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. |
| Q99725197 | The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson's Disease Dementia |
| Q89769611 | The Levodopa Response Varies in Pathologically Confirmed Parkinson's Disease: A Systematic Review |
| Q94540641 | The Neuropathologic Substrate of Parkinson Disease Dementia |
| Q64273363 | The Role of NOX4 in Parkinson's Disease with Dementia |
| Q27004240 | The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis |
| Q42248817 | The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease |
| Q47666324 | The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies |
| Q33724698 | The neurobiological basis of cognitive impairment in Parkinson's disease |
| Q22001062 | The prion hypothesis in Parkinson's disease: Braak to the future |
| Q37988384 | The significance of neuronal lateralisation in Parkinson's disease |
| Q34326923 | The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia |
| Q37596779 | Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. |
| Q30358337 | Treatment of psychosis and dementia in Parkinson's disease. |
| Q38038539 | Trial designs used to study neuroprotective therapy in Parkinson's disease |
| Q38219529 | Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues |
| Q37053794 | Verbal Memory in Parkinson's Disease: A Combined DTI and fMRI Study. |
| Q37974179 | Visual hallucinations in the differential diagnosis of parkinsonism |
| Q35203683 | Visuomotor control of neck surface electromyography in Parkinson's disease |
| Q36854793 | Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations |
| Q38753941 | ɑ-Synuclein strains and the variable pathologies of synucleinopathies |
| Q53827082 | α-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons. |
| Q36924335 | β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia |
Search more.